Cure8 research brief
The study identifies a fungal β-glucan that reduced inflammation and altered the gut microbiome and short-chain fatty acids in a mouse model of ulcerative colitis, which could inform future nutritional or therapeutic research relevant to UC.
Researchers studying microbiome-based therapies, clinicians interested in dietary bioactives for IBD support, and patients curious about emerging preclinical nutritional interventions.
This report describes preclinical (mouse) experiments using dextran sulfate sodium to induce colitis and then treating with scleroglucan.
The authors measured body weight, disease activity index, colonic inflammatory markers (TNF-α, MPO, IL-10), goblet cell markers (Muc2), short-chain fatty acids, expression of SCFA receptors (GPR41/43/109A), and changes in gut microbiota composition.
The study found improvements in several inflammation and microbiome-related readouts and increased cecal acetate, propionate, butyrate, and valerate. The authors frame scleroglucan as a candidate bioactive polysaccharide for developing functional foods to assist UC nutritional intervention.
This is preclinical laboratory research in mice, not a clinical trial, so it does not establish safety or effectiveness in people with IBD. Discuss any interest in supplements or dietary products with your clinician before making changes.
This is an animal study (DSS-induced colitis in mice) reported in a peer-reviewed journal abstract. Findings are preclinical and require further testing in humans before clinical application.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
The study identifies a gut bacteria–liver signaling axis (Lactobacillus johnsonii → hepatic LXRα–SCD1) that may explain how altered hepatic lipids contribute to UC and related liver injury, and shows pristimerin can...
The study describes a new oral, colon‑targeted delivery system that improved outcomes in a mouse model of ulcerative colitis and shifted immune and microbiome markers—research that could inform future therapies focused...
